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Background: Multiple myeloma (MM) is characterized by osteolytic bone disease resulting from increased osteoclast activity and 
reduced osteoblast function. Aim: The aim of our research was to determine connection between bone turnover markers and pres-
ence of bone lesions, their degree of severity, to monitor MM bone disease and to assess effectiveness of anti-myeloma treatment. 
Materials and Methods: Serum samples and clinical data from 123 patients with newly diagnosed MM were collected at Riga East 
Clinical University Hospital (Riga, Latvia) from June 2014 to June 2016. Bone lesions detected by radiography, CT scans, MRI, 
and PET/CT were divided into degrees from 0 to 3 (0 — no bone involvement, 1 — ≤ 3 bone lesions, 2 — ≥ 3 bone lesions, 3 — 
fracture). Staging was performed applying Durie/Salmon (DS) and International Staging System classifications. Progressive 
disease was defined as development of one or more new bone lesions. The levels of bone metabolic markers β-isomerized C-termi-
nal telopeptide of collagen type I (β-CTX) and bone-specific alkaline phosphatase (bALP) were monitored regularly in the year. 
Results: Bone lesions were found in 86 (69%) patients. From these 6 (4%) patients had 1st degree, 11 (9%) had 2nd degree and 
69 (56%) had 3rd degree bone lesions. Level of the bone resorption marker β-CTX in the control group was 0.41 ng/ml, which 
is lower than in MM patients (p < 0.001). Spearman correlation coefficient analysis found a positive and statistically significant 
correlation (rs = 0.51, p < 0.001) between bone lesions degree and β-CTX levels. Mean β-CTX for patients without bone lesions 
was 0.72 ng/ml (SD = 0.64), but for patients with 3rd degree bone lesions it was 1.34 ng/ml (SD = 0.65) difference being 38% 
(p < 0.001). In patients who responded to therapy after 6 months of treatment reduction of β-CTX was found compared to baseline 
values (M = –0.65). In contrast, in patients who did not respond to therapy, there was a statistically significant (p < 0.001) increase 
in β-CTX values after six months of treatment compared to baseline values (M = 0.42). Exact cutoff value of β-CTX is 0.79. When 
analyzing mean bALP, no significant difference between MM patients and control group was found. ANOVA statistical analysis 
showed no statistically significant differences in bALP levels at different degrees of bone lesions (p = 0.95) in MM patients. 
Analysis of bALP suitability as MM diagnostic marker using receiver operating characteristics curve showed that bALP is not 
applicable for clinical diagnosis of MM (AUC 0.5, p > 0.05). However, β-CTX was found to be an excellent diagnostic marker for 
MM (AUC 0.91; 95% confidence interval, 0.88–0.94; p < 0.001). Conclusions: Patients with MM and bone lesions have increased 
value of bone resorption marker β-CTX. There is a correlation between bone resorption marker and degree of bone lesions. 
Changes in β-CTX levels may be used to monitor the effectiveness of myeloma treatment.
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�ultiple myeloma ���� is a B-cell malignancy 
c�aracterized by proliferation of monoclonal plasma 
cells in t�e bone marrow. Bone lesions are a very com-
mon presenting feature in patients wit� ��� wit� lytic 
bone destruction being a debilitating manifestation 
of t�e disease [�]. Bone disease is typical of �� and 
its occurrence increases wit� t�e progression of t�e 
disease. Bone disease can substantially affect patient 
morbidity and quality of life [�]. �ost patients respond 
to initial treatment� but eventually almost all patients 
will �ave resistant relapse and die from t�e disease. 
Osteolytic lesions are seen in ���8�% of patients 
at diagnosis� w�ile up to ��% develop lytic lesions 
during t�e course of t�eir disease [�] and may cause 
skeletal-related event �SRE� wit� bone pain� pat�ologi-
cal fractures� spinal cord compression� �ypercalcemia 
and need to use radiation t�erapy or bone surgery [�]� 
but no tests �ave proven useful in identifying patients 
wit� increased risk for it.
�� is c�aracterized by a tig�t relations�ip wit� t�e 
bone microenvironment. �� cells induce a significant 
alteration of t�e bone remodeling process due to t�e 
increase of osteoclast formation and activation and 
to t�e suppression of osteoblast differentiation lead-
ing to t�e development of osteolytic lesions [�� 4��]. 
Bioc�emical markers of bone turnover may represent 
an alternative to evaluate t�e bone status of patients 
wit� myeloma. T�e activity of bone resorption and for-
mation is reflected by bone turnover markers �BT�s� 
offering information about t�e ongoing activity in bone 
degradation and formation [8].
Bone markers are classified as resorption and 
formation markers. Bone resorption markers are t�e 
degradation products of osteoclasts or collagen deg-
radation and bone formation markers are produced 
by osteoblastic cells or derived from procollagen 
metabolism. Bone resorption markers are degrada-
tion products of β-isomerized C-terminal telopeptide 
of collagen type I �β-CTX�� w�ic� constitutes ��% 
of t�e organic bone matrix and are �ig�ly specific for 
t�e degradation of type I collagen dominant in bone. 
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Bone formation markers are products of osteoblast ac-
tivity and include bone-specific alkaline p�osp�atase 
�bALP� representing membrane-bound osteoblast 
enzyme t�at is produced during bone formation. T�e 
aim of our researc� was to determine connection 
between BT�s and presence of bone lesions� t�eir 
degree of severity� to monitor �� bone disease and 
to assess effectiveness of anti-myeloma treatment.
MATERIALS AND METHODS
Serum samples and clinical data from ��� patients 
wit� newly diagnosed �� were collected at Riga 
East Clinical University Hospital �Riga� Latvia� from 
June ���4 to June ����. T�e patients enrolled in t�is 
study �� ���%� female and �� �4�%� male �ad an age 
range of ���8� years �median age was ��.�� years�. 
Blood samples �and related data� were accessed 
after informed consent from all patients. Eac� pa-
tient’s attending p�ysician decided on t�erapy regard-
less of data being researc�ed. Bone lesions at t�e time 
of diagnosis were detected using eit�er conventional 
radiograp�y� computed tomograp�y �CT� scans� mag-
netic resonance imaging ��RI� or positron emission 
tomograp�y �PET�/CT and were divided into degrees 
from � to � �� — no bone involvement� � — ≤ � bone 
lesions� � — ≥ � bone lesions� � — fracture or vertebral 
collapse� according to [�]. Staging was performed 
applying Durie/Salmon �DS� and International Sta ging 
System classification system. Progressive disease 
was defined as development of one or more new bone 
lesions.
Treatment included cyclop�osp�amide� bort-
ezomib� dexamet�asone� eryt�ropoietin� calcium� 
vitamin D and autologous stem cell transplantation. 
In addition� 4 patients were treated wit� low dose ra-
diot�erapy �up to �� Gy� in t�e course of treatment and 
� underwent vertebroplasty early in t�eir treatment. All 
patients wit� bone disease �excluding patients wit� 
glomerular filtration rate �GFR� < �� ml/min� received 
zoledronate at a dose of 4 mg every 4 weeks.
All analyzes were made wit�in t�e same laboratory. 
Bioc�emical markers of bone remodeling� namely 
β-CTX and bALP were measured by electroc�emilu-
minescence immunoassay ECLIA on Cobas analyzer 
�Roc�e Diagnostics� Germany� and c�emilumines-
cence immunoassay on t�e LIAISON analyzer �DiaSo-
rin� Inc.� USA�� respectively. Blood samples were col-
lected at regular intervals �every � mont�s over � year� 
at � o’clock in t�e morning from fasting patients. T�e 
samples were immediately centrifuged.
T�e control group comprised of ���8 age and 
sex matc�ed patients. Excluded from t�e study were 
bot� �� patients and control group patients w�ose 
conditions creates primary or secondary osteoporosis 
or bone lesions� are receiving medications t�at could 
potentially lead to osteoporosis and patients wit� GFR 
< �� ml/min/�.�� m�. T�e study design� patients’ 
information and consent forms were approved by t�e 
Et�ic Committee of t�e Riga Stradins University and 
conducted according to t�e national et�ical guidelines 
and t�e Helsinki Declaration.
Statistical analysis. IB� SPSS Statistics �� soft-
ware �IB�� USA� was used. Data were presented 
as mean ��� and standard deviation �± SD� or median 
��e� and interquartile range �IQR� for continuous 
variables� and counts and percentages [%] for cate-
gorical variables. Comparisons were made using 
t-test� �ann — W�itney test in case of non-normality 
and cate gorical variables were compared by Pear-
son’s χ� test. C�anges in time were compared by us-
ing ANOVA for repeated measures. T�e relations�ips 
between variables were evaluated using Spearman — 
Rank correlation coefficient �rs�. Receiver operating 
c�aracteristics �ROC� curve analysis was generated 
to test t�e predictive discrimination of �� patients wit� 
and wit�out bone lesions. T�e area under eac� ROC 
curve �AUC� was calculated as a measure of overall 
diagnostic power. Sensitivity �Se�� specificity �Sp�� 
positive �PPV� and negative predictive values �NPV� 
were determined according to standard definitions. 
Exact cutoff values for bone markers were determined 
based on t�e best balance of Se and Sp. All tests were 
considered statistically significant at p < �.��.
RESULTS AND DISCUSSION
Bone lesions were found in 8� ���.��%� patients. 
From t�ese � �4%� patients �ad �st degree� �� ��%� 
�ad �nd degree and �� ���%� �ad �rd degree bone le-
sions. Distribution between bone lesion localization was 
as follows: ��� patients �ad spinal lesions� �� — costal� 
�� — pelvic� � — �umeral� 4 — femoral and � — sternal. 
T�e most common combination of localizations were 
spinal wit� costal lesions toget�er �84 patients�. 8�% 
of t�e vertebral fractures occurred in T�VIII�LV region 
of t�e spine and ��% of t�em found in t�e T�XI�LI re-
gion. In DS system stage �� � and � were found in �4� 
�� and 8� patients� respectively� but using International 
Staging System classification �� patients �ad �st stage� 
�� — �nd stage and �� — �rd stage ��. Hypercalcemia 
was found in �� ���%� patients.
Statistical analysis s�owed t�at t�e average age 
of t�e control and study groups did not differ signifi-
cantly �t-test; p > �.���. Basic demograp�ic indicators 
are s�own in Table �.
Table 1. Basic demographic indicators
Indicators Control group Research group p value
Age (M ± SD) 65.01 ± 9.14 67.93 ± 9.97 > 0.05
Female/male, n (%) 846 (75.0)
282 (25.0)
70 (56.9)
53 (43.1)
> 0.05
T�e β-CTX levels in t�e control group was �.4� ng/ml 
�SD = �.���� w�ic� is statistically significantly lower 
t�an in �� patients �Table ��. Spearman correlation 
coefficient analysis found t�at between bone lesions 
degree and β-CTX level t�ere is a positive and statisti-
cally significant correlation �rs = �.��; p < �.����. �ean 
β-CTX for patients wit�out bone lesions was �.�� ng/ml 
�SD = �.�4�� but for patients wit� �rd degree bone le-
sions it was �.�4 ng/ml �SD = �.��� difference being 
�8%.
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In patients w�o responded to t�erapy� reduction 
of β-CTX was found compared to baseline values �∆� = 
��.���. In contrast� in patients w�o did not respond 
to t�erapy� t�ere was an increase in β-CTX values 
after � mont�s of treatment compared to baseline 
values �∆� = �.4�� �t-test� p < �.����. Value of β-CTX 
between �st and �nd collection of samples decreased 
in �� ���.��%� patients� but increased in �� ��8.�4%�. 
ANOVA repeated measures s�ows statistically signifi-
cant β-CTX decrease from t�e baseline value till �nd 
time of samples collection �after � mont�s� — �8%� but 
from �nd to �rd time �after a year of t�erapy� — ��.�% 
�p < �.����.
�ean β-CTX value depending on t�e effect 
of t�erapy is s�own in Table �. β-CTX cutoff value 
for �� patients depending on gender and age 
is �.����.8� �Table 4�. Exact cutoff value of β-CTX for 
all patients not adjusted for age and sex as diagnostic 
marker is �.�� ng/ml �Sp = ��% ���% CI: 88��4�; Se = 
8�% ���% CI: ���8��; PPV = ��% ���% CI: ������; 
NPV = ��% ���% CI: �������. Only 4�% of patients 
wit� no bone lesions �ave β-CTX value greater t�an 
�.��� w�ile �4% of patients wit� �st to �rd degree bone 
lesions �ave β-CTX value greater t�an �.��.
Table 3. Changes of β-CTX value depending on the effect of therapy
Patients β-CTX M ± SD  (min–max)
Difference (95% 
confidence inter-
val — CI), p value
Responding patients
Before treatment (n = 114) 1.12 ± 0.64 (0.11–4.09) –0.65 (0.41–0.66)
p < 0.001After 6 months therapy (n = 84) 0.47 ± 0.36 (0.03–1.77)
Non-responding patients
Before treatment (n = 9) 1.38 ± 0.74 (0.86–3.22) 0.42 (0.21–0.62)
p < 0.001After 6 months therapy (n = 9) 1.80 ± 0.92 (1.10–3.98)
W�en analyzing mean bALP� no significant difference 
between �� patients and control group was found. 
ANOVA statistical analysis s�owed no statistically sig-
nificant differences in bALP levels at different degrees 
of bone lesions �p = �.��� in �� patients. Value of bALP 
between �st and �nd collection of samples decreased 
in �� ��4.��%� patients� but increased in �� ���.48%�. 
Analysis of bALP suitability as �� diagnostic marker 
using ROC curve s�owed t�at bALP is not applicable 
for diagnosis �AUC = �.�; p > �.���. However� β-CTX 
was found to be an excellent diagnostic marker for �� 
�AUC = �.��; p < �.���; ��% CI: �.88��.�4� �Figure�.
Historically conventional radiograp�y — w�ole-
body X-rays — is t�e most common tec�nique for t�e 
evaluation of bone disease in �� patients. However� 
w�ole-body X-rays �as several limitations: it reveals 
lytic disease w�en over ��% of t�e trabecular bone �as 
been lost� w�ile it cannot be used for t�e assessment 
of response to t�erapy and it �as very low sensitivity 
for t�e pelvis and spine. T�us� w�ole-body low-dose 
CT can substitute conventional radiograp�y as t�e 
standard tec�nique for t�e evaluation of bone disea-
se in ��. Furt�ermore� lytic bone lesions detected 
by CT and �RI �ave been included in t�e new criteria 
for t�e definition of symptomatic �� [�����].
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Figure. bALP �a� and β-CTX �b� ROC curves wit� ��% CI for 
all patients
T�e lesions rarely �eal and bone scans are often 
negative in myeloma patients wit� extensive lytic le-
sions� offering very little in t�e follow-up of bone di-
sease [�4]. Wit� t�is strategy� substantial damage may 
�ave occurred in bone before t�e patient becomes 
symptomatic and progressive bone disease is detected.
Bioc�emical markers are not �armful and are 
compatible wit� mont�ly monitoring. T�ey �ave t�e 
potential to detect t�e destructive process as soon 
as it starts and before a lesion becomes detectable 
t�roug� conventional radiograp�y [8� ����8]. Data 
suggest t�at BT�s are useful prognostic factors 
t�at can predict patients’ risk of SREs� bone lesion 
progression� and deat�. BT�s can also be used 
to measure to biologic effects of antiresorptive medi-
cations �bisp�osp�onates� and to identify subgroups 
of patients w�o are at �ig� risk for disease progression 
and bone disease. BT�s could potentially be used 
as a tool for early diagnosis of bone lesions. �ar-
kers of bone metabolism s�ould be incorporated into 
clinical practice as a tool to manage malignant bone 
disease of �� patients [�� �����].
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